ArticleFrontiers in oncology2025
Efficacy and safety of pegylated recombinant human granulocyte colony-stimulating factor as a support for chemotherapy for gestational trophoblastic neoplasia: a propensity score matching analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gestational trophoblastic neoplasia (GTN) is a highly malignant tumor that can be effectively treated with chemotherapy alone. Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is used to reverse the adverse effects of chemotherapy, but its half-life is short, requiring daily injections and significantly reducing patient tolerance rates. Pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) can be administered for a longer duration, improving patient tolerance and compliance. This retrospective study was designed to investigate the efficacy and safety of PEG-rhG-CSF for preventing hematological toxicity after chemotherapy for GTN. Methods: We retrospectively assessed 200 GTN patients treated with chemotherapy from January 2019 to December 2021. One hundred patients received 6 mg of PEG-rhG-CSF within 24 h after chemotherapy and composed the experimental group. One hundred additional patients who were treated with recombinant human granulocyte colony-stimulating factor were matched 1:1 via the propensity score matching method and served as the control group. The main observations were differences in hematological toxicity, neutrophil changes, febrile neutropenia incidence and adverse reactions. Results: The incidences of grade 3/4 neutropenia, grade 4 neutropenia, febrile neutropenia, antibiotic use, chemotherapy delay and bone pain in the experimental group were significantly lower than those in the control group ( Conclusion: PEG-rhG-CSF has good efficacy and safety in preventing hematological toxicity in GTN patients after chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.